Investors wiped $70 billion off Novo Nordisk’s market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). These ...

Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO while simultaneously slashing its full-year guidance, citing weaker growth expectations for its blockbuster Wegovy obesity drug in ...

LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.